Financial Performance Highlights

Q2 FY27 Consolidated Performance

  • Revenue from Operations: INR 201 crore (66.5% increase YoY from INR 120 crore in Q2 FY26; 6.6% increase QoQ from Q1 FY27)
  • EBITDA: INR 26.96 crore (142% increase YoY)
  • EBITDA Margin: 13.25% (vs 9% in Q2 FY26, 420 bps improvement)
  • Net Profit: INR 14.89 crore (610% increase YoY from INR 2 crore)
  • Earnings Per Share: INR 12.78 (vs INR 1.91 in Q2 FY26)

H1 FY27 Consolidated Performance

  • Revenue from Operations: INR 390 crore (44% increase YoY)
  • EBITDA: INR 59.56 crore (157% increase YoY)
  • EBITDA Margin: 15.15% (vs 8.45% in H1 FY26, 670 bps improvement)
  • Net Profit: INR 33.92 crore (623% increase YoY)

Business Segment Performance

Blue Pigments (Phthalocyanine) Business:

  • Extremely strong quarter with improvement on every key measure
  • Revenue growth of ~47% in H1 FY27 over H1 FY26
  • Driven by strong supplier relationships, procurement structure, energy efficiencies, and cost discipline
  • Management confident of sustaining 13-15% EBITDA margins long-term
  • Q3 typically sees softness due to global inventory tightening by export customers
  • Q3 FY27 expected to be significantly better than Q3 FY26

AZO Pigments Business:

  • Challenging Q2 with performance below expectations
  • Q2 Revenue: INR 28.82 crore
  • H1 Revenue: INR 47.35 crore
  • Volumes grew but pricing remains tough with competitive pressure
  • Business is EBITDA positive and cash positive
  • Current utilization: 70-75%
  • Focus on winning larger customers, improving product quality, and reducing production costs
  • H2 FY27 expected to be better than H1 FY27
  • PBT breakeven target for FY27 remains achievable

API Business (Atlas Life Sciences):

  • Revenue increased ~33% in H1 FY27 over H1 FY26
  • Volumes have grown at ~18% annually for past 3 years
  • Price pressure continued to hold back performance
  • Business is EBITDA positive and cash positive
  • CEP (Certificate of Suitability) approval expected by March 2027 (possibly earlier)
  • Current utilization: Odhav facility ~95%; Chhatral facility ~40%
  • H2 FY27 expected to show improved performance with easing price pressures

Balance Sheet and Capital Allocation

  • Strong cash generation enabled reduction of gross borrowings by ~INR 49 crore
  • Deleveraging pace faster than expected since borrowing INR 200 crore
  • Lower debt reducing finance costs and providing considerable headroom
  • Company evaluating opportunities for next phase of growth (acquisitions, capacity expansion, or new projects)
  • Disciplined approach to capital allocation with focus on return on capital employed
  • Balance sheet described as strongest in company's history
  • Targeting debt-to-EBITDA below 1x and net worth-to-debt of 0.15x-0.20x

Volume Data (Provided by CFO Maulik Shah)

Blue Business:

  • H1 FY27: 4,691 tons vs 4,190 tons in H1 FY26
  • Q2 FY27: 2,357 tons vs 1,748 tons in Q2 FY26

AZO Business:

  • H1 FY27: 915 tons vs 907 tons in H1 FY26
  • Q2 FY27: 546 tons vs 497 tons in Q2 FY26

API Business:

  • H1 FY27: 196 tons vs 149 tons in H1 FY26
  • Q2 FY27: 99 tons vs 78 tons in Q2 FY26

Strategic Outlook and Guidance

  • Company targeting INR 900-1,000 crore revenue in next few years
  • H1 FY27 annualizes to ~INR 780 crore revenue
  • Growth expected from increased utilization of existing capacities with minimal CAPEX
  • AZO capacity can be increased by 1.5 tons with INR 10-15 crore investment when utilization reaches 85%
  • API business has significant room for utilization improvement (currently ~40% at Chhatral)
  • CEP approval expected to open European and semi-regulated markets, improving realizations
  • Company working on 8-10 additional API products including Levosulpiride, Amisulpride, and Phenylephrine
  • Management believes structural improvements will sustain performance beyond current period

Raw Material and Pricing Environment

  • Q1 included some inventory gains; Q2 is cleaner quarter without such benefits
  • Raw material prices have been volatile with recent uptrend due to geopolitical factors
  • Company maintains just-in-time inventory (approximately 2 weeks)
  • Strong supplier relationships help manage volatility better than competitors
  • Company positioned to perform well during volatile periods